Name: Amylyx Pharmaceuticals, Inc. (AMLX) Financial Statements
Creator: FinSpry

Amylyx Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Amylyx Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	87.37	380.79	22.23	0.29	0.65
Cost of Revenue	42.16	153.63	96.44	44.04	24.59
Gross Profit	45.22	227.16	-74.21	-43.76	-23.94
Operating Expenses
Research & Development	104.08	128.19	93.45	44.04	0.00
Selling, General & Administrative	114.33	188.36	127.13	38.93	15.06
Operating Expenses	359.95	188.36	127.13	38.93	15.06
Operating Income	-314.73	38.80	-201.34	-82.69	-39.01
Other Income/Expense
Interest Income	13.81	16.16	4.29	0.04	0.01
Interest Expense	0.00	0.00	0.00	0.00	-2.29
Other Income/Expense	12.60	-10.60	-2.61	0.07	-1.27
Income
Income Before Tax	-302.14	54.30	-197.60	-87.93	-42.28
Income Tax Expense	-0.39	5.03	0.77	0.00	0.00
Net Income	-301.74	49.27	-198.38	-87.93	-42.28
Net Income - Continuous Operations	-301.74	49.27	-198.38	-87.93	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-290.98	39.89	-200.85	-82.64	-39.00
EBIT	-302.14	38.80	-201.34	-82.69	-39.01
Depreciation & Amortization	0.90	1.09	0.49	0.05	0.00
Earnings Per Share
Basic EPS	-4.00	1.00	-3.00	-13.00	-7.00
Diluted EPS	-4.00	1.00	-3.00	-13.00	-7.00
Basic Shares Outstanding	68.14	67.23	58.50	6.59	6.08
Diluted Shares Outstanding	68.14	69.99	58.50	6.59	6.08